Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia.
| Autor: | Connell NT; Hematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Caicedo J; US Medical Affairs, Takeda Pharmaceuticals USA Inc, Lexington, MA, USA., Nieto N; US Medical Affairs, Takeda Pharmaceuticals USA Inc, Lexington, MA, USA., Chatterjee S; Complete HEOR Solutions, North Wales, PA, USA., Hait A; Complete HEOR Solutions, North Wales, PA, USA., Gupta AK; Complete HEOR Solutions, North Wales, PA, USA., Bullano M; US Medical Affairs, Takeda Pharmaceuticals USA Inc, Lexington, MA, USA., Schultz BG; US Medical Affairs, Takeda Pharmaceuticals USA Inc, Lexington, MA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2023 Jul-Dec; Vol. 23 (6), pp. 691-699. Date of Electronic Publication: 2023 May 15. |
| DOI: | 10.1080/14737167.2023.2211270 |
| Abstrakt: | Objective: To describe the economic burden among VWD patients with angiodysplasia compared to VWD patients without angiodysplasia and the general population. Methods: This was a retrospective analysis using the Merative MarketScan Commercial and Medicare Databases® (January 2011-September 2020). Selected patients had ≥1 medical claim for VWD or low VWF, ≥1 medical claim for AGD, and ≥3 GI-related bleeding episodes within a year. HCRU and all-cause costs were compared with the VWD (only) and the general cohorts. Results: The mean total all-cause costs were $150,101 among patients with VWD and angiodysplasia ( n = 34), higher compared to $48,249 among matched VWD patients without angiodysplasia ( n = 136) and $31,029 among matched individuals of the general population [ n = 136; p-value < 0.0001]. The differences in costs between groups were primarily due to inpatient care. During the 12-month follow-up, VWD patients with symptomatic ( n = 35), asymptomatic ( n = 81), and suspected ( n = 378) angiodysplasia had an average of 4.1, 0.6, and 3.8 gastrointestinal (GI) bleeds, respectively. Desmopressin, VWF concentrates, and aminocaproic acid were the most frequent treatments used. The most frequent procedures to treat GI-related bleeding and underlying lesions were blood transfusion and laser therapy. Conclusions: Despite recent therapeutic advances, there is room for considerable reduction of the disease burden in patients with VWD and angiodysplasia. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|